Glaukos Corporation (NYSE:GKOS) is set to announce third quarter earning results on Thursday 5th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, GKOS to report 3Q20 loss of $ 0.48 per share.
For the full year, analysts anticipate top line of $ 208.39 million, while looking forward to loss of $ 1.84 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 290.00 million ~ $ 300.00 million
Click Here For More Historical Outlooks Of Glaukos Corporation
Previous Quarter Performance
Glaukos Corporation posted loss for the second quarter of $ 0.61 per share, from the revenue of $ 31.56 million. The quarterly revenues declined 46.14 percent compared with the same quarter last year. According to street consensus, GKOS was expected to report 2Q20 loss of $ 0.76 per share from revenue of $ 20.06 million. The bottom line results beat street analysts by $ 0.15 or 19.74 percent, at the same time, top line results outshined analysts by $ 11.50 million or 57.33 percent.
Stock Performance
Shares of Glaukos Corporation traded up $ 0.77 or 1.39 percent on Wednesday, reaching $ 56.02 with volume of 363.20 thousand shares. Glaukos Corporation has traded high as $ 57.71 and has cracked $ 54.95 on the downward trend
The closing price of $ 56.02, representing a 137.02 % increase from the 52 week low of $ 23.31 and a 22.14 % decrease over the 52 week high of $ 70.96.
The company has a market capital of $ 2.50 billion and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Recent Analyst recommendations
- On 8th October 2020, downgraded by JPMorgan Chase & Co. to Underweight from Neutral rating.
Conference Call
Glaukos Corporation will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.glaukos.com
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery. The companys product pipeline includes iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma; iStent Supra suprachoroidal micro-bypass stent that is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; iStent SA trabecular micro-bypass system, a two-stent product, which uses a different auto-injection inserter designed for use in a standalone procedure; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration.
